Hybrids of Imatinib with Quinoline: Synthesis, Antimyeloproliferative Activity Evaluation, and Molecular Docking

Imatinib (IMT) is the first-in-class BCR-ABL commercial tyrosine kinase inhibitor (TKI). However, the resistance and toxicity associated with the use of IMT highlight the importance of the search for new TKIs. In this context, heterocyclic systems, such as quinoline, which is present as a pharmacoph...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Carine, Pimentel, Luiz, Canzian, Henayle, Oliveira, Andressa, Junior, Floriano, Dantas, Rafael, Hoelz, Lucas, Marinho, Debora, Cunha, Anna, Bastos, Monica, Boechat, Nubia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950477/
https://www.ncbi.nlm.nih.gov/pubmed/35337107
http://dx.doi.org/10.3390/ph15030309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950477/
https://www.ncbi.nlm.nih.gov/pubmed/35337107
http://dx.doi.org/10.3390/ph15030309

Ejemplares similares